Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.62 USD

0.62
785,018

+0.02 (3.06%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $0.62 0.00 (-0.51%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.

Why Amarin (AMRN) Stock Might be a Great Pick

by Zacks Equity Research

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $6.68, marking a -1.18% move from the previous day.

Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.

Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

by Zacks Equity Research

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Amarin's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Amarin.

Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat

by Zacks Equity Research

Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.

Amarin (AMRN) Meets Earnings Estimates in Q1, Revenues Tops

by Zacks Equity Research

Amarin's (AMRN) first quarter earnings were in line with expectations. However, sales beats estimates. Stock down.

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

by Zacks Equity Research

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Is Amarin (AMRN) Stock a Solid Choice Right Now?

by Zacks Equity Research

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amarin's Stock Plunges Following Unfavorable Patent Ruling

by Zacks Equity Research

Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.

Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed the most recent trading day at $18.72, moving -0.58% from the previous trading session.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed at $19.40 in the latest trading session, marking a +0.41% move from the prior day.

AstraZeneca to End Phase III Study on Fish Oil Heart Drug

by Zacks Equity Research

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

by Zacks Equity Research

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%

by Zacks Equity Research

BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Applied Therapeutics Up on Positive Galactosemia Study Data

by Zacks Equity Research

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

by Zacks Equity Research

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

Why Amarin (AMRN) Stock Might be a Great Pick

by Zacks Equity Research

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.